TL32711
TL32711 is a small molecule peptidomimetic of Smac that is mechanistically differentiated from other classes of cancer drugs. It potently and specifically antagonizes multiple inhibitors of apoptosis proteins (IAPs), resulting in caspase-dependent apoptosis and inactivation of NF-κB survival signaling. Preclinical studies have shown that TL32711 causes tumor-regressions as a single agent and that it has potent anti-tumor activity when combined with chemotherapies and death receptor ligands.
TL32711 Clinical Development
In Phase 1 clinical studies as a single agent and in combination with standard-of-care chemotherapies, TL32711 has demonstrated strong correlation between drug exposure, target coverage and apoptosis induction in tumors at well-tolerated doses as well as promising anti-tumor activity in patients.
TL32711 is entering Phase 2 single agent and combination clinical studies in solid tumors and a Phase 1/2 clinical study in acute myeloid leukemia. TetraLogic will execute a Phase 2 clinical program to explore the broad therapeutic potential of Smac mimetics with the support of substantial non-dilutive funding that reduces downstream equity requirements.
TL32711 Single Agent Therapy
TL32711 Combination Therapy
